PCVX — Vaxcyte Inc
NASDAQ · Biotechnology · Biotechnology
- Latest Close
- $59.49
- 30-Day Move
- +38.2%
- Market Cap
- $8.0B
- Shares Outstanding
- 143,920,000
- P/B Ratio
- 2.25
- ROE
- -28.5%
Analyst consensus: Buy · 17 analysts
Vaxcyte Inc
A read-only Alphactor snapshot forVaxcyte Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-24
Topline snapshot
Latest Close
$59.49
30-Day Move
+38.2%
Market Cap
$8.0B
Shares Outstanding
143,920,000
P/B Ratio
2.25
ROE
-28.5%
$59.49
+38.2%last 90 delayed daily bars
90D High
$65.00
90D Low
$42.40
Avg Volume
1,333,252
PCVX is up 38.2% over the last 30 trading days shown on this page.
Latest operating income is $-274M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$59.49
30-Day Move
+38.2%
Market Cap
$8.0B
Shares Outstanding
143,920,000
P/B Ratio
2.25
ROE
-28.5%
ROA
-25.5%
Debt / Equity
0
Current Ratio
7.91
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-274M
Net Income
$-247M
Gross Margin
--
Net Margin
--
Current Ratio
7.91
Debt / Equity
0.00
Altman Z
13.77
Safe
Piotroski
1
Weak (0-3)
Cash Conversion
0.86x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-209M | $-223M | $-176M |
| 2023-12-31 | $0 | $-393M | $-402M | $-365M |
| 2024-12-31 | $0 | $-570M | $-464M | $-572M |
| 2025-12-31 | $0 | $-924M | $-767M | $-713M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$0
Sell Value
$2M
Buys
0
Sells
11
Buy Value
$0
Sell Value
$2M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-07 | Cowan Elvia | M | 3,000 | $0.00 |
| 2026-04-07 | Cowan Elvia | Sell | 3,000 | $60.00 |
| 2026-04-07 | Cowan Elvia | M | 3,000 | $25.92 |
| 2026-04-01 | Wassil Jim | Sell | 838 | $58.93 |
| 2026-04-01 | Wassil Jim | Sell | 1,412 | $58.14 |
| 2026-03-17 | Cowan Elvia | Sell | 405 | $56.26 |
| 2026-03-17 | Cowan Elvia | Sell | 1,487 | $55.39 |
| 2026-03-11 | Cowan Elvia | M | 2,500 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4,101,947 | 0.03% | 2025-12-31 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 3,283,168 | 0.02% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 ETF | 3,020,405 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2,967,660 | 0.02% | 2025-12-31 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2,781,675 | 0.02% | 2026-02-28 |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 2,570,623 | 0.02% | 2025-12-31 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2,094,593 | 0.01% | 2025-12-31 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1,916,700 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-05-15
--
--
BlackRock
Filed 2024-08-13
$751M
--
FMR LLC (Fidelity)
Filed 2026-02-17
$638M
+10.6%
Vanguard Group
Filed 2026-01-29
$563M
-1.0%
Capital Research Global Investors
Filed 2025-05-12
$231M
--
D.E. Shaw
Filed 2026-02-17
$168M
-15.4%
Geode Capital Management
Filed 2026-02-09
$132M
-0.6%
4.29
Consensus
Buy—
—
—
17
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.